![](/img/cover-not-exists.png)
A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours
Infante, Jeffrey R., Papadopoulos, Kyriakos P., Bendell, Johanna C., Patnaik, Amita, Burris, Howard A., Rasco, Drew, Jones, Suzanne F., Smith, Lon, Cox, Donna S., Durante, Michael, Bellew, Kevin M., PVolume:
49
Language:
english
Journal:
European Journal of Cancer
DOI:
10.1016/j.ejca.2013.03.020
Date:
June, 2013
File:
PDF, 448 KB
english, 2013